CA-YOU.COM
6.3.2024 02:17:34 CET | Business Wire | Press release
You.com announces its designation as one of the few new default browser options on iOS 17.4 for European Union users, alongside significant updates to its AI-powered mobile browsing app, You.com AI Search and Browse.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305667601/en/
Newly Revamped You.com AI Search and Browse App Now Available on iOS 17.4 in the European Union as Part of New Browser Choice Screen (Graphic: Business Wire)
The inclusion in the iOS browser choice screen today highlights You.com's increasing global popularity and dedication to delivering a cutting-edge AI-powered web search and browsing experience loved by its users.
“We're excited to share the latest update to our You.com AI Search and Browse app, now available as a default browser choice on iOS 17.4 for users throughout the European Union. As the only AI chat-native browser option on the new EU browser choice screen for iOS, You.com is setting a new standard for what a browser can do thanks to AI,” said Richard Socher, CEO of You.com.
Socher continued: “With the introduction of 'Ask AI' and a fresh, intuitive app design, we're not just updating features, we're enhancing how you find information online. You.com is more than another way to search and browse — it's an AI Assistant designed to make you more productive, creative, and extraordinary. We invite you to make You.com your default browser for a smarter way to find answers.”
What’s new:
- Introducing “Ask AI”: Dive into the future of search with our new "Ask AI" feature, delivering AI-powered answers complete with citations for a more informative and trustworthy browsing experience.
- A fresh, updated experience: Enjoy a cleaner, more intuitive interface with our updated app design, making navigation smoother and more enjoyable than ever before.
- Enhanced mobile homepage: Discover what's trending with an improved mobile home page that now offers trending suggestions, keeping you informed and engaged with the latest and most relevant content.
With You.com, users can say goodbye to endless scrolling through blue links and tedious websites. Search alone is inefficient for in-depth research, and ineffective at answering complex, multi-step questions. A conversational search experience powered by cutting-edge AI, You.com delivers immediate, comprehensive answers across any topic, supplemented by follow-up suggestions for deeper exploration.
You.com enhances the efficiency of finding information and enriches the quality of results with advanced AI functionalities that support text generation, content summarization, image creation, and more. You.com stands out for its powerful AI Modes, from its Research Mode which can browse and synthesize information from multiple websites simultaneously with extensive citations to its Genius Mode capable of multi-step complex problem solving.
Whether users prefer traditional search methods or the enriched, AI-enhanced search, You.com offers seamless management of searches, chats, and visited websites, with easy options for saving or deleting history. Linked citations further empower users to verify responses and delve into sources, ensuring a trustworthy and comprehensive browsing experience.
You.com also prioritizes privacy, offering ad-blocking, pop-up blocking, and tracking protection capabilities.
Download You.com today for free and experience a better way to search.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305667601/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom